research use only
Cat.No.S7648
|
In vitro |
DMSO
: 30 mg/mL
(69.93 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 428.97 | Formula | C23H24N2O2S.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1338545-07-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=CC(=C(C2=C1NC(=O)C3=C2C=CS3)C4=CC=C(C=C4)C(C)CN(C)C)O.Cl | ||
| Targets/IC50/Ki |
TOPK
(Cell-free assay) 28 nM
CDK11B
(Cell-free assay) 40 nM(Kd)
|
|---|---|
| In vitro |
OTS964 inhibits the growth of TOPK-positive cells with low IC50 values [A549 (31 nM), LU-99 (7.6 nM), DU4475 (53 nM), MDAMB- 231 (73 nM), T47D (72 nM), Daudi (25 nM), UM-UC-3 (32 nM), HCT-116 (33 nM),MKN1 (38 nM), MKN45 (39 nM), HepG2 (19 nM), MIAPaca-2 (30 nM), and 22Rv1 (50 nM)], whereas its growth inhibitory effect against TOPK-negative HT29 cancer cells is significantly weaker, with IC50 of 290nM. Although this compound reveals some suppressive effect on Src family kinases, the response to this chemical in these cancer cells is not correlated with the expression of Src family kinases c-Src, Fyn, and Lyn, supporting the TOPK-dependent growth inhibitory effects of this compound. Time lapse imaging in T47D cells shows that treatment with this agent induces cytokinesis defects followed by apoptosis. |
| In vivo |
Although administration of the free compound induces hematopoietic adverse reactions (leukocytopenia associated with thrombocytosis), the drug delivered in a liposomal formulation effectively causes complete regression of transplanted tumors without showing any adverse reactions in mice. Inhibition of TOPK activity with the liposomal formulation suppresses tumor growth through induction of cytokinesis defects and subsequent apoptosis. Although oral administration of this compound causes some hematopoietic toxicity, this is a transient effect. The spontaneous recovery from leukocytopenia is occured and the anticancer effectiveness of the oral drug is similar to that of the liposomal formulation, oral administration of the drug may prove to be more practical. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p62 / LC3-I / LC-3Ⅱ / p-Histone H3 / Histone H3 / TOPK ULK1 / p-ATG13 / ATG13 / p-Beclin-1 / Beclin-1 |
|
31378785 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.